V. Klinghofer

发表

Design and synthesis of pyridine-pyrazolopyridine-based inhibitors of protein kinase B/Akt.

V. Stoll, Eric F. Johnson, X. Liu, 2007, Bioorganic & medicinal chemistry.

The PARP inhibitor, ABT-888 potentiates temozolomide: correlation with drug levels and reduction in PARP activity in vivo.

Eric F. Johnson, X. Liu, V. Giranda, 2008, Anticancer research.

Potentiation of Temozolomide Cytotoxicity by Poly(ADP)Ribose Polymerase Inhibitor ABT-888 Requires a Conversion of Single-Stranded DNA Damages to Double-Stranded DNA Breaks

Eric F. Johnson, X. Liu, V. Giranda, 2008, Molecular Cancer Research.

Discovery of trans-3,4'-bispyridinylethylenes as potent and novel inhibitors of protein kinase B (PKB/Akt) for the treatment of cancer: Synthesis and biological evaluation.

V. Stoll, Eric F. Johnson, X. Liu, 2006, Bioorganic & medicinal chemistry letters.

Cardiovascular Effects and Hemodynamic Mechanism of Action of the Novel, Nonpeptidic Renin Inhibitor A‐74273 in Dogs

P. Kovar, H. Kleinert, J. Wessale, 1993, Journal of cardiovascular pharmacology.

Immunochemical detection of inducible NO synthase in human lung.

R. Johns, J. Pollock, U. Förstermann, 1994, The American journal of physiology.

Species specificity of amidine-based urokinase inhibitors.

P. Richardson, V. Giranda, S. Dorwin, 2001, Biochemistry.

Optimal classes of chemotherapeutic agents sensitized by specific small-molecule inhibitors of akt in vitro and in vivo.

J. Fisher, X. Liu, V. Giranda, 2005, Neoplasia.

Directly photocrosslinked nucleotides joining transfer RNA to aminoacyl-tRNA synthetase in methionine and tyrosine systems.

A. Joachimiak, P. Sigler, E. Ackerman, 1985, Journal of molecular biology.

Synthesis and structure-activity relationship of 3,4'-bispyridinylethylenes: discovery of a potent 3-isoquinolinylpyridine inhibitor of protein kinase B (PKB/Akt) for the treatment of cancer.

V. Stoll, Eric F. Johnson, X. Liu, 2006, Bioorganic & medicinal chemistry letters.

Isoxazolo[3,4-b]quinoline-3,4(1H,9H)-diones as unique, potent and selective inhibitors for Pim-1 and Pim-2 kinases: chemistry, biological activities, and molecular modeling.

Eric F. Johnson, N. Soni, V. Giranda, 2008, Bioorganic & medicinal chemistry letters.

Novel potent and selective inhibitors of inducible nitric oxide synthase.

M. Nakane, J. Pollock, J. Kuk, 1995, Molecular pharmacology.

Identification of a novel 3,5-disubstituted pyridine as a potent, selective, and orally active inhibitor of Akt1 kinase.

Eric F. Johnson, X. Liu, V. Giranda, 2006, Bioorganic & medicinal chemistry letters.

Functional expression of three isoforms of human nitric oxide synthase in baculovirus-infected insect cells.

H. Esumi, M. Nakane, J. Pollock, 1995, Biochemical and biophysical research communications.

Synthesis and SAR of indazole-pyridine based protein kinase B/Akt inhibitors.

Eric F. Johnson, X. Liu, V. Giranda, 2006, Bioorganic & medicinal chemistry.

Optimization of phenyl-substituted benzimidazole carboxamide poly(ADP-ribose) polymerase inhibitors: identification of (S)-2-(2-fluoro-4-(pyrrolidin-2-yl)phenyl)-1H-benzimidazole-4-carboxamide (A-966492), a highly potent and efficacious inhibitor.

Eric F. Johnson, X. Liu, V. Giranda, 2010, Journal of Medicinal Chemistry.

ABT-888 , an OrallyActive Poly ( ADP-Ribose ) Polymerase Inhibitor that Potentiates DNA-Damaging Agents in PreclinicalTumorModels

Eric F. Johnson, T. DeWeese, X. Liu, 2007 .

ABT-888, an Orally Active Poly(ADP-Ribose) Polymerase Inhibitor that Potentiates DNA-Damaging Agents in Preclinical Tumor Models

Eric F. Johnson, T. DeWeese, X. Liu, 2007, Clinical Cancer Research.

Discovery and SAR of 2-(1-propylpiperidin-4-yl)-1H-benzimidazole-4-carboxamide: A potent inhibitor of poly(ADP-ribose) polymerase (PARP) for the treatment of cancer.

Eric F. Johnson, X. Liu, V. Giranda, 2008, Bioorganic & medicinal chemistry.

Synthesis and SAR of novel, potent and orally bioavailable benzimidazole inhibitors of poly(ADP-ribose) polymerase (PARP) with a quaternary methylene-amino substituent.

Eric F. Johnson, X. Liu, V. Giranda, 2008, Bioorganic & medicinal chemistry letters.

Discovery of a new cyclooxygenase-2 lead compound through 3-D database searching and combinatorial chemistry.

K. Stewart, K. Hulkower, K D Stewart, 1998, Bioorganic & medicinal chemistry letters.

Discovery of the Poly(ADP-ribose) polymerase (PARP) inhibitor 2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide (ABT-888) for the treatment of cancer.

Eric F. Johnson, X. Liu, V. Giranda, 2009, Journal of medicinal chemistry.

Discovery of a peptide-based renin inhibitor with oral bioavailability and efficacy.

P. Kovar, S. Rosenberg, H. Kleinert, 1992, Science.

Identification of novel binding interactions in the development of potent, selective 2-naphthamidine inhibitors of urokinase. Synthesis, structural analysis, and SAR of N-phenyl amide 6-substitution.

V. Giranda, M. Wendt, V. Nienaber, 2004, Journal of medicinal chemistry.

Isoquinoline-pyridine-based protein kinase B/Akt antagonists: SAR and in vivo antitumor activity.

V. Stoll, Eric F. Johnson, X. Liu, 2006, Bioorganic & medicinal chemistry letters.

Discovery and SAR of oxindole-pyridine-based protein kinase B/Akt inhibitors for treating cancers.

Eric F. Johnson, X. Liu, V. Giranda, 2006, Bioorganic & medicinal chemistry letters.

Potent and selective inhibitors of Akt kinases slow the progress of tumors in vivo

Yan Shi, V. Stoll, Eric F. Johnson, 2005, Molecular Cancer Therapeutics.

C-terminal modifications of nonpeptide renin inhibitors: improved oral bioavailability via modification of physicochemical properties.

D. Egan, W. Baker, J. Cohen, 1992, Journal of medicinal chemistry.

Studies directed toward the design of orally active renin inhibitors. 2. Development of the efficacious, bioavailable renin inhibitor (2S)-2-benzyl-3- [[(1-methylpiperazin-4-yl)sulfonyl]propionyl]-3-thiazol-4-yl-L-alanine amide of (2S,3R,4S)-2-amino-1-cyclohexyl-3,4-dihydroxy-6-methylheptane (A-7251

P. Kovar, S. Rosenberg, J. Polakowski, 1993, Journal of medicinal chemistry.

Nonpeptide renin inhibitors with good intraduodenal bioavailability and efficacy in dog.

J. Wessale, K. Verburg, W. Baker, 1994, Journal of medicinal chemistry.

Structure-directed discovery of potent non-peptidic inhibitors of human urokinase that access a novel binding subsite.

Jean M. Severin, R A Smith, V. Giranda, 2000, Structure.

Endothelial nitric oxide synthase is myristylated

F. Murad, J. Pollock, U. Förstermann, 1992, FEBS letters.

Hit to Lead optimization of a novel class of squarate-containing polo-like kinases inhibitors.

A. Vasudevan, Eric F. Johnson, V. Giranda, 2012, Bioorganic & medicinal chemistry letters.

Interaction with the S1 beta-pocket of urokinase: 8-heterocycle substituted and 6,8-disubstituted 2-naphthamidine urokinase inhibitors.

V. Giranda, M. Wendt, V. Nienaber, 2004, Bioorganic & medicinal chemistry letters.

Syntheses of potent, selective, and orally bioavailable indazole-pyridine series of protein kinase B/Akt inhibitors with reduced hypotension.

V. Stoll, G. Gintant, Eric F. Johnson, 2007, Journal of medicinal chemistry.

The nitric oxide synthase inhibitor, L-NG-monomethylarginine, reduces carrageenan-induced pleurisy in the rat.

M. Nakane, J. Kuk, G. Carter, 1995, The Journal of pharmacology and experimental therapeutics.

Pseudosubstrate peptides inhibit Akt and induce cell growth inhibition.

P. Richardson, T. Holzman, X. Liu, 2004, Biochemistry.

Naphthamidine urokinase plasminogen activator inhibitors with improved pharmacokinetic properties.

Milan Bruncko, V. Giranda, D. Sauer, 2005, Bioorganic & medicinal chemistry letters.

Discovery of the Poly(ADP-ribose) polymerase (PARP) inhibitor 2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide (ABT-888) for the treatment of cancer.

Eric F. Johnson, X. Liu, V. Giranda, 2009, Journal of medicinal chemistry.